Replies to post #236389 on Biotech Values

[DewDiligence]

(REGN)—FDA accepts Roche’ Faricimab BLAs_for AMD/DME/DR—with_priority_review:

https://www.businesswire.com/news/home/20210728006055/en

Faricimab is a bi-specific mAb that targets VEGF-A and Ang-2.